Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.61 |
| ▸ | NOS2 | P35228 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30689573 | 1.00 | NOS3 (0.61) | NOS3NOS2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL18689678 | 0.80 | ALDH1A1 (0.43) | NOS3NOS2SMN1; SMN2S1PR2ALDH1A1 | |
| SCHEMBL21922822 | 0.79 | NOS3 (0.41) | NOS3NOS2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3711167 | 0.77 | MEN1 (0.47) | NOS3NOS2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29849205 | 0.77 | MEN1 (0.47) | NOS3NOS2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL165100 | 0.77 | — | — | |
| SCHEMBL16454931 | 0.77 | PGK1 (0.38) | NOS3NOS2S1PR2PGK1CYP2C19 | |
| SCHEMBL19225767 | 0.77 | TRPM8 (0.42) | NOS3NOS2S1PR2ALDH1A1POLB | |
| SCHEMBL943294 | 0.76 | NOS3 (1.00) | NOS3NOS2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2771693 | 0.75 | NOS3 (0.35) | NOS3NOS2SMN1; SMN2S1PR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4320112-B1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20240376082-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-11-14 | — | — | US | disclosed |
| EP-4320112-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230303527-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-28 | — | — | US | disclosed |
| US-11718601-B2 | Pyridinyl substituted oxoisoindoline compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-08 | — | — | US | disclosed |
| WO-2022216644-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220324840-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2022-10-13 | — | — | US | disclosed |
| EP-2789606-B1 | Modulators of CFTR | VERTEX PHARMA (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-3004110-B1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-07-26 | — | — | EP | disclosed |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | PGXHEALTH, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | PGXHEALTH, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-7732455-B2 | Substituted 8-heteroaryl xanthines | PGX HEALTH, LLC (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732455-B2 | Substituted 8-heteroaryl xanthines | PGX HEALTH, LLC (US) | 2010-06-08 | — | — | US | disclosed |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ALLERGAN SALES, LLC | 2008-08-21 | — | — | US | disclosed |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ALLERGAN SALES, LLC | 2008-08-21 | — | — | US | disclosed |
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718601-B2 | Pyridinyl substituted oxoisoindoline compounds | HNRNPH3, RPL17, RTF2 | NOS3 2409/4885NOS2 2258/4885SMN1; SMN2 669/4885 |
| US-20240376082-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS | HNRNPH3, RPL17, RTF2 | NOS3 2409/4885NOS2 2258/4885SMN1; SMN2 669/4885 |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ADORA2B, ADORA2A, ADORA3 | NOS3 2978/4885NOS2 3119/4885SMN1; SMN2 3702/4885 |
| US-20230303527-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS | HNRNPH3, RPL17, RTF2 | NOS3 2409/4885NOS2 2258/4885SMN1; SMN2 669/4885 |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | ADORA2B, ADORA2A, ADORA3 | NOS3 2978/4885NOS2 3119/4885SMN1; SMN2 3702/4885 |
| US-20220324840-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS | HNRNPH3, RPL17, RTF2 | NOS3 2409/4885NOS2 2258/4885SMN1; SMN2 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.